Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of lipoic acid combination with valsartan on diabetic nephropathy and associated adverse reactions

Minqin Wang¹, Jiaying Luo², Jisu Xue¹

¹Department of Endocrinology, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, China; ²Department of Endocrinology, Shenzhen Baoan Shiyan People’s Hospital, Shenzhen, Guangdong 518000, China.

For correspondence:- Jisu Xue Email: 13510505059@163.com

Accepted: 8 July 2024 Published: 31 July 2024

Citation: Wang M, Luo J, Xue J. Effect of lipoic acid combination with valsartan on diabetic nephropathy and associated adverse reactions. Trop J Pharm Res 2024; 23(7):1127-1133 doi: 10.4314/tjpr.v23i7.11

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of lipoic acid combination with valsartan on diabetic nephropathy (DN) and its associated adverse reactions.

Methods: A retrospective analysis was conducted on 120 patients who treated for DN at the Second Affiliated Hospital of Shenzhen University, China between August 2019 and October 2022. Based on different treatment approaches, control group comprised 55 patients receiving valsartan alone, while joint group consisted of 65 patients receiving a combination of valsartan and lipoic acid. Therapeutic effectiveness and adverse events were compared between the groups. Additionally, changes in blood glucose and renal function parameters were evaluated pre- and post-treatment.

Results: Post-treatment, both groups exhibited improvements in blood glucose and renal function parameters compared to pre-treatment values (p < 0.05). However, joint group demonstrated superior improvements in these parameters compared to control group (p < 0.05). Total efficacy was significantly higher in the joint group than in control group (p < 0.05). No significant differences were observed between the groups' incidence of adverse reactions (p > 0.05).

Conclusion: Concurrent therapy of lipoic acid and valsartan sly treats DN. It enhances the regulation of blood glucose levels and improves renal function with high safety. Further studies employing larger sample sizes and prospective designs with comprehensive patient follow-up are required to further validate and enhance the reliability of these findings.

Keywords: Lipoic acid, Valsartan, Diabetic nephropathy, Adverse reactions